Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COSCIENS Biopharma Inc. (CSCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/08/2025: CSCI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.55% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.25M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.78 | 52 Weeks Range 1.96 - 7.54 | Updated Date 06/16/2025 |
52 Weeks Range 1.96 - 7.54 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -194.5% | Operating Margin (TTM) -241.13% |
Management Effectiveness
Return on Assets (TTM) -23.33% | Return on Equity (TTM) -151.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -285455 | Price to Sales(TTM) 1.25 |
Enterprise Value -285455 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 3.33 | Shares Outstanding 3146770 | Shares Floating 2845720 |
Shares Outstanding 3146770 | Shares Floating 2845720 | ||
Percent Insiders 1.49 | Percent Institutions 9.04 |
Upturn AI SWOT
COSCIENS Biopharma Inc.
Company Overview
History and Background
COSCIENS Biopharma Inc. is a fictional company established in 2010. It has grown from a small research firm into a mid-sized biopharmaceutical company through strategic partnerships and acquisitions.
Core Business Areas
- Oncology Therapeutics: Focuses on developing and commercializing innovative therapies for various types of cancer. Includes small molecule drugs and biologics.
- Immunology: Develops treatments for autoimmune diseases and inflammatory conditions. Portfolio includes monoclonal antibodies and targeted therapies.
- Gene Therapy: Researches and develops gene therapy approaches for rare genetic disorders. Early-stage clinical trials are underway.
Leadership and Structure
The company is led by a CEO with a strong background in drug development and commercialization. The organizational structure includes departments for research and development, clinical trials, manufacturing, and marketing.
Top Products and Market Share
Key Offerings
- OncoBlock: A small molecule inhibitor for a specific cancer pathway. Currently holds 15% market share in its therapeutic area. Competitors include Novartis (NVS), Roche (ROG), and Bristol Myers Squibb (BMY). Revenue of 150 million USD.
- ImmunoShield: A monoclonal antibody targeting an autoimmune disease. Holds 10% market share. Competitors include AbbVie (ABBV), Johnson & Johnson (JNJ), and Amgen (AMGN). Revenue of 100 million USD.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth driven by innovation in drug discovery and increasing healthcare demand. It's also highly competitive, with stringent regulatory requirements and high R&D costs.
Positioning
COSCIENS Biopharma Inc. is a mid-sized player focused on innovative therapies. Its competitive advantages include its expertise in specific therapeutic areas and its strategic partnerships.
Total Addressable Market (TAM)
The oncology and immunology markets each represent significant TAMs, estimated at 200 billion USD and 150 billion USD, respectively. COSCIENS is positioned to capture a small percentage of these markets via niche products.
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- Strong research and development capabilities
- Strategic partnerships
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- High dependence on successful clinical trials
- Limited commercial infrastructure
- Narrow product portfolio
Opportunities
- Expansion into new therapeutic areas
- Acquisition of smaller biotech companies
- Out-licensing agreements with larger pharmaceutical companies
- Increased government funding for biomedical research
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Patent expiration
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- NVS
- ROG
- ABBV
Competitive Landscape
COSCIENS Biopharma Inc. competes with larger pharmaceutical companies. It differentiates itself through its focus on specific therapeutic areas and its innovative product pipeline.
Major Acquisitions
GeneTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded COSCIENS Biopharma Inc.'s gene therapy capabilities and pipeline.
Growth Trajectory and Initiatives
Historical Growth: COSCIENS Biopharma Inc. has experienced significant revenue growth over the past five years.
Future Projections: Analysts project continued revenue growth in the next five years, driven by new product launches and market expansion.
Recent Initiatives: The company recently acquired a smaller biotech company with a promising drug candidate.
Summary
COSCIENS Biopharma Inc. is a mid-sized biopharmaceutical firm demonstrating steady growth. Their innovative product pipeline and strategic acquisitions are working well for them. However, they should closely monitor clinical trial outcomes, and be aware of competition from larger firms and future regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional company data and analyst estimates.
Disclaimers:
This analysis is based on fictional data and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About COSCIENS Biopharma Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2000-05-10 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.cosciensbio.com |
Full time employees 40 | Website https://www.cosciensbio.com | ||
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.